Humacyte director buys 10,000 shares at $0.562

A Humacyte director increased his direct common stock holdings through an open-market purchase.

Rhea-AI Filing Summary

Humacyte, Inc. (HUMA) director Keith Anthony Jones purchased additional common shares. On September 14, 2026, he bought 10,000 shares of Humacyte common stock in an open-market or private transaction at $0.562 per share. After this purchase, he holds 50,000 shares directly. No Rule 10b5-1 trading plan is reported for this transaction.

Insider Trade Summary

Net Buyer: 10,000 shares

Net Buy 1 txn

Insider Jones Keith Anthony

Role Director

Bought 10,000 shs ($6K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	10,000	$0.562	$6K

Holdings After Transaction: Common Stock — 50,000 shares (Direct)

Key Figures

Shares purchased: 10,000 shares Purchase price: $0.562 per share Shares held after transaction: 50,000 shares

3 metrics

Shares purchased 10,000 shares Common stock bought by director on September 14, 2026

Purchase price $0.562 per share Price paid for Humacyte common stock on September 14, 2026

Shares held after transaction 50,000 shares Director’s direct Humacyte common stock holdings after the purchase

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did HUMA report in this Form 4?

Humacyte reported that director Keith Anthony Jones purchased 10,000 shares of common stock on September 14, 2026 in an open-market or private transaction.

How many Humacyte (HUMA) shares did the director buy and at what price?

Keith Anthony Jones purchased 10,000 Humacyte common shares at a price of $0.562 per share on September 14, 2026.

What are the director’s total Humacyte (HUMA) holdings after this transaction?

Following the reported purchase, director Keith Anthony Jones directly holds 50,000 shares of Humacyte common stock.

Was the Humacyte (HUMA) insider purchase made under a Rule 10b5-1 trading plan?

No. The filing indicates that this insider purchase by director Keith Anthony Jones was not made under a Rule 10b5-1 trading plan.

Is the Humacyte (HUMA) director’s ownership direct or indirect after the purchase?

After the September 14, 2026 transaction, the 50,000 shares reported as held by director Keith Anthony Jones are held directly.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 04:05 PM Accepted by SEC EDGAR 09/15/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jones Keith Anthony

(Last) (First) (Middle)

2525 EAST NORTH CAROLINA HIGHWAY 54

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Humacyte, Inc. [ HUMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/14/2026		P		10,000	A	$0.562	50,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Keith A. Jones by Dale A. Sander as Attorney-in-Fact	09/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)